MARKER THERAPEUTICS, INC. Disposal Group, Including Discontinued Operation, Operating Expense
MARKER THERAPEUTICS, INC. (MRKR) reported Disposal Group, Including Discontinued Operation, Operating Expense of $7.24 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense · last filed 2025-03-31
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2023-12-31 was -$1.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2023-06-30 was $3.00M.
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2022-12-31 was $3.36M.
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for fiscal 2023 was $7.24M, a 53.76% decline from fiscal 2022.
- MARKER THERAPEUTICS, INC. disposal group, including discontinued operation, operating expense for fiscal 2022 was $15.65M.
| Period end | Disposal Group, Including Discontinued Operation, Operating Expense 3 month | Disposal Group, Including Discontinued Operation, Operating Expense 6 month | Disposal Group, Including Discontinued Operation, Operating Expense 9 month | Disposal Group, Including Discontinued Operation, Operating Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.00 derived: sum of 2 quarters · filed 2025-03-31 | $3.00M derived: sum of 3 quarters · filed 2025-03-31 | $7.24M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $3.00M derived: sum of 2 quarters · filed 2024-11-14 | $7.24M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-14 | $7.24M 10-Q · filed 2024-08-14 | ||
| 2022-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $7.51M derived: sum of 2 quarters · filed 2024-03-26 | $15.65M 10-K · filed 2024-03-26 | |
| 2022-09-30 | $4.14M 10-Q · filed 2023-11-09 | $12.29M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |